Literature DB >> 21833023

Associations of serum salusin-alpha levels with atherosclerosis and left ventricular diastolic dysfunction in essential hypertension.

Y Ti1, F Wang, Z-h Wang, X-l Wang, W Zhang, Y Zhang, P-l Bu.   

Abstract

Serum salusin-alpha, is decreased in essential hypertension and acute coronary syndrome. The study is aimed to explore whether serum salusin-alpha is associated with atherosclerosis and left ventricular (LV) diastolic dysfunction in essential hypertension. Echocardiography, carotid ultrasonography, brachial-ankle pulse wave velocity (BaPWV) and serum salusin-alpha levels were determined in 60 hypertensive patients (29 with and 31 without carotid plaque) and 30 normotensive controls. Hypertensive patients with plaque, compared with those without plaque or the controls, had the lowest values of salusin-alpha. Then the hypertensive patients were divided into left ventricular hypertrophy (LVH) and non-LVH groups according to the echocardiography. Similarly, hypertensive patients with LVH showed the lowest serum salusin-alpha levels. In all subjects, serum salusin-alpha levels were negatively correlated with carotid mean-intima-media thickness (IMT), BaPWV, left ventricle mass index (LVMI) and E/E' (r=-0.488, P<0.001; r=-0.381, P<0.001; r=-0.294, P=0.006; r=-0.303, P=0.005; respectively). Serum salusin-alpha levels were independent predictors of BaPWV, carotid strain, carotid distensibility, mean-IMT, LVMI and E'/A' (β=-0.399, 0.283, 0.237, -0.346, -0.306, 0.469; P=0.002, 0.031, 0.016, 0.005, 0.012 and 0.001, respectively) in multiple linear regression models. These results suggest that serum salusin-alpha may be associated with atherosclerosis and LV diastolic dysfunction in essential hypertension.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21833023     DOI: 10.1038/jhh.2011.71

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  10 in total

1.  Relationship of salusin-alpha and salusin-beta levels with atherosclerosis in patients undergoing haemodialysis.

Authors:  Savas Sipahi; Ahmed Bilal Genc; Seyyid Bilal Acikgoz; Mehmet Yildirim; Yakup Ersel Aksoy; Mehmet Bulent Vatan; Hamad Dheir; Mustafa Altındis
Journal:  Singapore Med J       Date:  2018-10-10       Impact factor: 1.858

2.  Serum salusin-α levels in systemic lupus erythematosus and systemic sclerosis.

Authors:  Süleyman Serdar Koca; Metin Özgen; Bahar Işık; Mustafa Necati Dağlı; Bilal Üstündağ; Ahmet Işık
Journal:  Eur J Rheumatol       Date:  2014-03-01

3.  The role of serum salusin alpha and beta levels and atherosclerotic risk factors in idiopathic sudden hearing loss pathogenesis.

Authors:  Sena Genç Elden; Mahmut Sinan Yılmaz; Mustafa Altındiş; Mehmet Köroğlu; Halil Elden
Journal:  Eur Arch Otorhinolaryngol       Date:  2021-04-18       Impact factor: 2.503

Review 4.  Endogenous bioactive peptides as potential biomarkers for atherosclerotic coronary heart disease.

Authors:  Takuya Watanabe; Kengo Sato; Fumiko Itoh; Kohei Wakabayashi; Masayoshi Shichiri; Tsutomu Hirano
Journal:  Sensors (Basel)       Date:  2012-04-18       Impact factor: 3.576

Review 5.  Salusins: potential use as a biomarker for atherosclerotic cardiovascular diseases.

Authors:  Kengo Sato; Rena Watanabe; Fumiko Itoh; Masayoshi Shichiri; Takuya Watanabe
Journal:  Int J Hypertens       Date:  2013-10-22       Impact factor: 2.420

6.  Increased serum salusin-α by aerobic exercise training correlates with improvements in arterial stiffness in middle-aged and older adults.

Authors:  Shumpei Fujie; Natsuki Hasegawa; Kiyoshi Sanada; Takafumi Hamaoka; Seiji Maeda; Jaume Padilla; Luis A Martinez-Lemus; Motoyuki Iemitsu
Journal:  Aging (Albany NY)       Date:  2020-01-09       Impact factor: 5.682

7.  Is the serum level of salusin-β associated with hypertension and atherosclerosis in the pediatric population?

Authors:  Urszula Kołakowska; Elżbieta Kuroczycka-Saniutycz; Anna Wasilewska; Witold Olański
Journal:  Pediatr Nephrol       Date:  2014-09-23       Impact factor: 3.714

8.  Circulating levels of human salusin-β, a potent hemodynamic and atherogenesis regulator.

Authors:  Kazumi Fujimoto; Akinori Hayashi; Yuji Kamata; Akifumi Ogawa; Takuya Watanabe; Raishi Ichikawa; Yoshitaka Iso; Shinji Koba; Youichi Kobayashi; Takatoshi Koyama; Masayoshi Shichiri
Journal:  PLoS One       Date:  2013-10-03       Impact factor: 3.240

9.  Salusin-β not salusin-α promotes vascular inflammation in ApoE-deficient mice via the I-κBα/NF-κB pathway.

Authors:  Cheng-Hua Zhou; Lian Liu; Lu Liu; Ming-Xing Zhang; Hao Guo; Jin Pan; Xiao-Xing Yin; Teng-Fei Ma; Yu-Qing Wu
Journal:  PLoS One       Date:  2014-03-12       Impact factor: 3.240

Review 10.  Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1, Salusin-α and -β, Uromodulin, and Adropin.

Authors:  Mirjam Močnik; Nataša Marčun Varda
Journal:  Children (Basel)       Date:  2022-01-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.